RELATIONSHIP OF THE MARKERS OF ENDOTHELIAL DYSFUNCTION AND FIBROSIS IN CHRONIC HEPATITIS AND CIRRHOSIS

The aim – assessing the relationship of markers of endothelial dysfunction and fibrosis (AF) in patients with chronic viral hepatitis and liver cirrhosis (LC).

Materials and methods. We examined 40 patients with chronic hepatitis C in the phase of reactivation. The second group included 15 patients with viral CP in stage of decompensation. Using the method of ELISA tests was studied evaluating the functional state of endothelium in the blood serum with a level of total nitrogen oxide (OA), endothelin-1 (ET-1), vascular-endothelial growth factor (VEFR). Evaluated the functional activity of Willebrand factor (WF), calculated the number of desquamated endothelial cells (DETS) in blood plasma, determined the level of hyaluronic acid (HA) in serum. Established diagnostic sensitivity (Qh), specificity (DS) and efficiency (DE) of laboratory parameters.

Results. In chronic hepatitis (CH) found an inverse significant relationship of HA and OA, and direct relationship with Civil ET-1, VEFR, WF, indicating the association of fibrosis with the severity of the damage of the endothelium. Patients with CKD also had a direct correlation between HA and ET-1,VEFR, PV. Ratio of aspartate and alanine aminotransferase (AST/ALT) with hCG was associated with OA, ET-1, VEFR, DETS. In patients with CKD significant coefficient de Rytis nteractions with OA, ET-1, VEFR are found. At the point of separating the concentration of SC > 120.0 ng / ml for the diagnosis of CKD has Qh 92 %, FS –76 %, DE – 82 %. In evaluating the operating characteristics of the indicators of endothelial dysfunction capacity of tests to stratify CG and CP were installed, the sensitivity was 73–92 %, specificity – 50–96 %, and efficiency – 69–86 %.

Conclusion. CG and CP demonstrated the relationship of indicators of endothelial dysfunction with markers OP – HA, AST/ALT. The results suggest that indicators of endothelial damage may serve as indirect markers of AF.

1. Wynn A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199–210.

2. Friedrich-Rust М., Rosenberg W., Parkes J. et al. Comparison of ELF, FibroTest and FibroScan for the noninvasive assessment of liver fibrosis. BMC Gastroenterology 2010;10:103.

3. Saitou Y., Shiraki K., Yamanaka Y. et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11(4):476–81.

4. Meigs J.B., Hu F.B., Rifai N., Manson J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004;297:1978–86.

5. Hon W.M., Lee W.H., Khoo H.E. Nitric oxide in liver diseases: friend, foe, or just passerby? Ann N Y Acad Sci 2002;962:275–95.

6. Щекотова А.П. Дисфункция и повреждение эндотелия при гепатобилиарной патологии. Уральский медицинский журнал 2010;1:96–9.

7. Петрищев Н.Н., Беокович О.А. Диагностическая ценность определения десквамированных эндотелиоцитов в крови. Клиническая лабораторная диагностика 2001;1:50–2.

8. Власов В.В. Введение в доказательную медицину. М.: МедиаСфера, 2001.

9. Giannini E., Risso D., Botta F. et al. Validity clinicalutility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virusrelated chronic liver disease. Arch Intern Med 2003;163:218–24.